Last reviewed · How we verify
Live Combined Bifidobacterium and Lactobacillus
At a glance
| Generic name | Live Combined Bifidobacterium and Lactobacillus |
|---|---|
| Also known as | Live combined Bifidobacterium and Lactobacillus solution infusion through colonoscopy |
| Sponsor | First Affiliated Hospital Xi'an Jiaotong University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Biotics Intervention Oriented to Rescue From Environmental Pollution Inflammatory Responses (NA)
- Efficacy of Repeated Transcranial Magnetic Stimulation Combined With a Live Probiotic Tablet (Combined Bifidobacterium, Lactobacillus, Enterococcus and Bacillus Cereus Tablets, Live) in Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D) (PHASE1)
- Effect of Probiotic Supplements on Gastric Cancer Patients Receiving Neoadjuvant Chemotherapy (NA)
- A 12-weeks Study to Evaluate the Dietary Fiber and Probiotics Treatment in Prevention and Intervention of Weight-gain and Cognitive Impairment of Schizophrenia or Bipolar Disorder (NA)
- Role and Mechanism of Probiotics in Improving Motor Symptoms in Mild to Moderate Parkinson's Disease (PHASE4)
- Clinical Study on BIFICO Accelerating Postoperative Liver Function Recovery in Patients With Hepatocellular Carcinoma (NA)
- Effect of Live Combined Bifidobacterium and Lactobacillus on Glycemic Control and Other Outcomes in Type 1 Diabetes (PHASE4)
- Colonoscopic Probiotics Infusion for Functional Gastrointestinal Disease (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: